Sino Biological's XPressMAX™ Kit Cuts Antibody Synthesis to 3 Hours

Sino Biological, Inc., a global leader in recombinant technology listed on the Shenzhen Stock Exchange (301047.SZ), has launched the XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02), a revolutionary tool designed to accelerate AI-driven high-throughput screening for antibody drug discovery. The kit enables ultra-fast protein and antibody synthesis in just three hours, bypassing the limitations of traditional cell-based expression systems. By leveraging an E. coli lysate fully supplemented with transcription and translation components, XPressMAX™ allows direct protein synthesis from plasmid or PCR templates, making it ideal for expressing VHH, scFv, Fab, and Miniprotein formats. The company has already established a high-throughput cell-free expression platform that validates over 2,000 scFv/VHH molecules in 3-4 weeks, matching the rapid iteration pace of AI screening. Key highlights include a greater than 99% success rate and support for complex disulfide bonding, ensuring native folding and bioactivity without additional enhancers. Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc., emphasized that the kit is a significant advancement in research tools for next-generation therapeutic discovery, helping partners compress antibody discovery timelines without compromising quality. Dr. Jie Zhang, General Manager, noted that AI demands expression systems that can match its speed and throughput, and XPressMAX™ delivers rapid, high-success expression of challenging proteins. Researchers can explore more about XPressMAX™ at www.sinobiological.com or click here to request a free sample. Sino Biological, with its US-based Center for Bioprocessing (C4B) in Houston and SignalChem Biotech in Canada, serves researchers in over 90 countries, providing tailored solutions for diverse research needs.

The launch of XPressMAX™ marks a pivotal moment in the convergence of synthetic biology and artificial intelligence. Traditional antibody discovery relies on cell-based expression, which can take days to weeks and often fails for complex proteins. By reducing synthesis time to three hours and achieving over 99% success, XPressMAX™ removes a critical bottleneck in high-throughput screening. This allows AI algorithms to iterate rapidly on antibody candidates, significantly speeding up the identification of lead molecules for therapeutic development. The kit's ability to handle disulfide bond formation natively is particularly important for maintaining the bioactivity of antibodies and their fragments. For researchers in pharmaceutical and biotechnology companies, this means shorter development cycles and lower costs, potentially bringing life-saving therapies to patients faster. Sino Biological's integrated platform, combining the kit with their high-throughput expression service, offers a comprehensive solution for the entire discovery pipeline from gene to validated protein. As AI continues to transform drug discovery, tools like XPressMAX™ will be essential for realizing its full potential, enabling the rapid testing of millions of design hypotheses in silico and in vitro.